Claudia Giambartolomei

2 months ago | nature.com | Danielle Rasooly |Claudia Giambartolomei |Gina M. Peloso |Maik Pietzner |Eric Farber-Eger |Lawrence Phillips | +4 more

AbstractHeart failure (HF) has limited therapeutic options. In this study, we differentiated the pathophysiological underpinnings of the HF subtypes—HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF)—and uncovered subtype-specific therapeutic strategies. We investigated the causal roles of the human proteome and transcriptome using Mendelian randomization on more than 420,000 participants from the Million Veteran Program (27,799 HFrEF and 27,579 HFpEF cases).

Nov 3, 2024 | nature.com | Umut Berkay Altıntaş |Claudia Giambartolomei |Geoffrey Nelson |Seth Goldman |Karen Adelman |Matthew Freedman

AbstractAndrogen receptor (AR)-mediated transcription plays a critical role in development and prostate cancer growth. AR drives gene expression by binding to thousands of cis-regulatory elements (CRE) that loop to hundreds of target promoters. With multiple CREs interacting with a single promoter, it remains unclear how individual AR bound CREs contribute to gene expression.

Jun 28, 2024 | medrxiv.org | Liam Gaziano |Elias Allara |Claudia Giambartolomei |David Stacey

J.P.C. moved to work with Novartis Institute for Biomedical Research during the completion of this project. E.W. is now an employee of AstraZeneca. A.S.B. reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and Sanofi. J. Danesh serves on scientific advisory boards for AstraZeneca, Novartis and the UK Biobank and has received multiple grants from academic, charitable and industry sources outside of the submitted work. Scott C.

Mar 24, 2024 | medrxiv.org | Danielle Rasooly |Claudia Giambartolomei |Gina M. Peloso |Hesam Dashti

The authors have declared no competing interest. This research is based on data from the Million Veteran Program at the Office of Research and Development at the Veterans Health Administration and this work was supported by awards #MVP037 [BLR&D Merit Award BX005831] and Veterans Affairs Grant I01CX001922 (PI: Joseph) and #MVP001 [I01-BX004821]. This publication does not represent the views of the Department of Veterans Affairs or the United States Government.

Dec 6, 2023 | nature.com | François Serra |Iker Núñez-Carpintero |Stefano Gustincich |Alfonso Valencia |Matthew Freedman |Claudia Giambartolomei

AbstractWe introduce Promoter-Enhancer-Guided Interaction Networks (PENGUIN), a method for studying protein-protein interaction (PPI) networks within enhancer-promoter interactions. PENGUIN integrates H3K27ac-HiChIP data with tissue-specific PPIs to define enhancer-promoter PPI networks (EPINs). We validated PENGUIN using cancer (LNCaP) and benign (LHSAR) prostate cell lines.